Meriva® – Curcumin Indena Phytosome™
Browse all Indena’s documents about products, events, company information and so much more.
Go to section
See through science
Meriva® – Curcumin Indena Phytosome™
Scroll to see more
Peer-reviewed science on Meriva®
Meriva® stands as the most pre-clinically and clinically documented bioavailable curcumin formulation.
Pharmacokinetics innovation5
According to clinical evidence comparing the pharmacokinetics profile of Meriva® and a reference standard turmeric extract, curcuminoid bioabsorption was about 29-fold higher for Meriva® than for its corresponding unformulated curcuminoid mixture (Fig.1).
Figure 1: Total curcuminoids (ng/mL) absorption profile after oral administration of Meriva® (high dose, dots; low dose, squares) and reference standard (triangles).
A safe approach2
The administration of Meriva® at a daily dose of 1.2 g/day, for up to 18 months, hasn't caused any discomfort or significant side effects on 106 participants.
Kidney health support 3,4
Low grade inflammation and oxidative stress are recognized among the disrupting factor for renal functionality and kidney health. In two recent human studies Meriva® have been tested to verify its potential to maintain normal and physiological renal values in subjects with diverse risk factors. 3,4
The first study has been conducted on 87 asymptomatic subjects that experienced a temporary kidney dysfunction, which implies a transient alteration of kidney parameters. The ancillary administration of 1.5 g/day of Meriva® significantly reduced albuminuria, oxidative stress and fatigue, after 4 weeks compared to the standard management (Fig.2).3
Furthermore, a brand-new study showed that Meriva® (1.0g/die) is associated to the decrease of fat mass, inflammation (Fig.3) and oxidation in subjects (n=24) with low and moderate levels of renal impairment.
Figure 2: Albuminuria (mg/L) in subjects treated with SM vs SM+Meriva® at V0 and after 4 weeks, considering microalbuminuria and macroalbuminuria values.
Figure 3: Levels of IL-4 and IFN-γ in subjects supplemented with Meriva® at T0, T1 and T2 (six months).
More evidence on MERIVA® PHYTOSOME®
Meriva® is active on broad spectrum of conditions, supported by over 40 human studies.
01.
Improvement of the exercise-related discomfort, stiffness and physical function (measured with the WOMAC score). Optimization of the healthy inflammatory response marker (C-reactive protein).5
02.
Healthy blood-vessel-function support.6 6
03.
Muscle soreness and stress relief, antioxidant and healthy inflammatory response optimization in case of prolonged physical exercise. 7,8
04.
Strength and physical performance improvement and lean-body mass loss prevention in the elderly.9
05.
Bone density optimization in asymptomatic subjects with bone-density challenges.11
BIBLIOGRAPHY
1Cuomo J. et al., J Nat Prod. Mar 17. (2011).
2Allegri P. et al., Clinical Ophtalmology 4, 1201-1206. (2010).
3Ledda A. et al., Panminerva Medica.Dec 61(4):444-8. (2019).
4Pivari F. et al., Nutrients,.Jan 14 231. (2022).
5Belcaro G. et al., Panminerva Medica, 52 (2 Suppl.1), 55-62.(2010).
6Appendino G. et al., Panminerva Medica, 53 (3 Suppl 1):43-9.(2011).
7Drobnic F. et al., J Int Soc Sports Nutr. Jun 18;11:31. (2014).
8Sciberras JN. et al, J Int Soc Sports Nutr. Jan 21;12(1):5. (2015).
9Franceschi F. et al., Eur Rev Med Pharmacol Sci; 20(4):762-6.(2016).
10Dugall M. et al., Eur Rev Med Pharmacol Sci, 21 1684-9. (2017).
